Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'

By G. Drusano. Nature Reviews Microbiology, 2004

953 citations recorded by the source corpus.

Subfields: Clinical Biochemistry, Molecular Medicine, Pharmacology

View Paper: https://www.semanticscholar.org/paper/e530a1cbf47f0acf177ef31bf45c83bfc7ff3b23

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Clinical Biochemistry

1. J. Lipman
2. J. Roberts
3. B. Lomaestro
4. J. Rotschafer

In Pharmacology

1. J. Roberts
2. J. Lipman
3. B. Lomaestro
4. J. Rotschafer

Citations in the corpus

• Diagnosis and Management of Complicated Intra-Abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America (2010, neutral): “Pharmacokinetic-pharmacodynamic properties of specific antibiotics should be considered in selecting an adequate dosage regimen [144].”
• Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association (2015, background): “Both β-lactam therapy alone and combination therapy with nafcillin and an aminoglycoside for only 2 weeks have been effective in patients with uncomplicated right-sided IE caused by S aureus91; monotherapy with a β-lactam would be selected for use in cases of uncomplicated IE.92 Of interest, right-s”
• DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? (2014, background): “Whereas animal in vivo studies have defined an f T>MIC between 40% and 70% of the dosing interval as being necessary [11], retrospective clinical evaluations have suggested that larger drug exposures are required, with β-lactam concentrations up to 4 times the MIC for the entire dosing interval bein”
• Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Socie (2020, methodology): “The early AUC/MIC target ratios derived in animal models were based on the AUC value from 0 to 24 hours.(3,4) More recent clinical assessments that identified a link between AUC/MIC ratio and outcomes also assessed the AUC values achieved early in the course of therapy.”